Human disease is shaped by a complex interplay of genetic and environmental influences. We bring you an unprecedented view into dynamic factors beyond the genome that modulate health, disease, and drug response.
Sapient’s multi-omics studies deliver the most dynamic omics data per sample to help decipher the heterogeneity in disease biology and patient response. We integrate multiple omics layers to analyze individual molecular changes – such as altered proteins or metabolites – within a broader biological context.
These approaches uncover functional biomarkers and entire pathways involved in disease and drug response, enabling more effective therapeutic development.
To understand functional biology, identify key drug targets, and elucidate how protein variants & modifications influence disease.
To uncover the dynamic downstream effects of disease, exposures, and therapeutic interventions and map distinct physiological states.
To quantify immune signaling mediators for insight into how immune biology is activated or dysregulated in disease or treated states.
To identify genetic variation associated with disease risk and assess patterns of gene expression.
We partner to provide this data for full multi-omics scope. We can also integrate our omics datasets with genomics and transcriptomics data as part of our biocomputational analyses.
The result? Deeper biological context to bridge the gap from inferred to actual biology.
By integrating varied multi-omics datasets, we can orthogonally validate findings and extend discoveries made through single omic studies, bringing you:
Directly interrogate functional biology that DNA and RNA can only infer – confirming disease and drug response mechanisms to meaningfully de-risk translation.
Our proven methods deliver high-precision, tightly QC’ed datasets at scale, across omics workflows – layered to validate hypotheses and extend discovery.
Our multi-omics studies include data interpretation to accelerate your ability to make critical go/no-decisions and prioritize R&D investments.
With broad biomarker coverage to enable comprehensive:
With functional evidence for:
With robust biomarkers to optimize:
See novel findings from a study combining cytokine profiling, discovery proteomics, and discovery metabolomics to characterize changes in inflammatory markers following weight loss intervention.
Our multi-omics studies benefit from biological contextualization in Sapient’s DynamiQ database – a large-scale, longitudinal reference dataset comprised of:
Build confidence in observed targets and
biomarkers by contextualizing their disease & clinical links in independent cohorts.
Elucidate associations of observed biomarkers with dynamic health and disease trajectories.
Reveal correlated biomarker patterns within and across diseases to unlock disease subtypes and/or indication expansion opportunities.
See how Sapient is leading the way for clients to go beyond the genome in their multi-omic analyses.
Multi‑omics studies integrate multiple molecular data types – such as metabolites, lipids, proteins, cytokines, DNA, and RNA – to provide a more complete view of human biology. Rather than analyzing each layer in isolation, multi‑omics approaches examine how different biological systems interact to drive disease and drug response.
Sapient is able to deliver the most dynamic omics data per sample, with workflows that include:
We also partner to provide DNA sequencing, bulk RNA sequencing, and single-cell sequencing services to generate data that helps link upstream regulation to downstream functional outcomes.
Sapient’s biocomputational approaches are designed to integrate, contextualize, and interpret complex multi‑omics datasets, transforming high‑dimensional molecular data into decision‑ready biological insights.
We apply scalable statistical modeling, pathway‑level analysis, and ML/AI-based algorithms to link molecular signals across omics layers, validate findings orthogonally, and connect results to clinical phenotypes using DynamiQ™. This ensures insights are biologically meaningful, reproducible, and actionable rather than purely descriptive.
Multi‑omics studies are particularly valuable for researchers and R&D teams that are seeking to:
By directly measuring multiple layers of functional biology, from metabolic flux to cytokine signaling, multi‑omics studies can confirm whether hypotheses derived from genomics or transcriptomics hold true in real biological systems. This multi‑modal evidence reduces the risk of pursuing targets or biomarkers that will ultimately fail to translate.
You can also explore our case studies and data published in collaboration with our clients to see how our multi-omics studies are delivering new insights to pharma and academic researchers.
DynamiQ provides a population-scale molecular‑clinical database in which to confirm and biologically contextualize findings uncovered in your study. It enables cross-validation of biomarkers and targets in independent human samples, disease‑trajectory mapping, biomarker‑disease association analyses, and identification of biologically distinct subgroups.
DynamiQ can also be used before any sample analysis begins, using the multi-omics data generated in our pre-characterized samples to scout for potential biomarkers or test early hypotheses in our virtual cohorts.
Connect with our scientists to discuss your project or the biological questions you want to answer. We’re here to help you design and execute a high-impact multi-omics study.
"*" indicates required fields
